The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Amgen; Atara Biotherapeutics; Celgene; CovACE Nanotechnology; crispr therapeutics; EUSA Pharma; Kite/Gilead; WUGEN, Inc.
Research Funding - Amgen; Kite, a Gilead company
Trial in progress: A phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-I7 (efineptakin alfa), a long-acting human IL-7, post-tisagenlecleucel in subjects with relapsed/refractory large B-cell lymphoma.
 
Armin Ghobadi
No Relationships to Disclose
 
L Elizabeth Budde
Consulting or Advisory Role - BeiGene; Kite/Gilead; Novartis; Roche/Genentech
Research Funding - Amgen; AstraZeneca; Merck; MustangBio
Patents, Royalties, Other Intellectual Property - CCR4 CAR T cells for treatment of patients with CCR4 positive cancer.; CD33CAR for treatment of patients with CD33+ acute myeloid leukemia.
Travel, Accommodations, Expenses - Kite/Gilead; Roche/Genentech
 
Ahmed Galal
Consulting or Advisory Role - Kite, a Gilead Company; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Incyte; Kite, a Gilead Company
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Incyte; Kite, a Gilead Company
 
Kristina Stermer
No Relationships to Disclose
 
TaShara Lynn Austin
Employment - NeoImmuneTech
 
Jean Fan
Employment - NeoImmuneTech
Leadership - NeoImmuneTech
Stock and Other Ownership Interests - AstraZeneCa, NeoImmuneTech, Inc
 
John F. DiPersio
Stock and Other Ownership Interests - Magenta Therapeutics; WUGEN, Inc.
Honoraria - Incyte
Consulting or Advisory Role - Amgen; Incyte; Magenta Therapeutics; Partner Therapeutics; Rivervest
Research Funding - Amphivena Therapeutics (Inst); Bigelow Aerospace (Inst); BiolineRx (Inst); Incyte (Inst); Macrogenics (Inst); Maxcyte (Inst); NeoImmuneTech (Inst); WUGEN, Inc. (Inst)
Patents, Royalties, Other Intellectual Property - CD7 and CD2 Knockout for CART to CD7 and CDL; Combining integrin inhibitor with chemokine binders, 016131; Dextran based molecules to detect CAR-T cells; Duvelisib for treatment of cytokine release syndrome (CRS); IFNg, upregulate MHCII for relapsed AML; JAK and calcineurin inhibition, solid organ transplant; Novel WU mobilizing compounds (Inst); NT-17 to enhance CART Survival; Selection of IMPDH Mutant Stem Cells; Targeting IFNR/CSCR3 in GvHD; Triple Combination - CXCR2, VLA-4, gro-b; VLA4, gro-b; WU/SLU compounds VLA4 and CXCR2 (Inst)
Travel, Accommodations, Expenses - Amgen; Celgene; Cerus; Incyte; Novartis; Partner Therapeutics